122 related articles for article (PubMed ID: 3209285)
61. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia.
Garré ML; Relling MV; Kalwinsky D; Dodge R; Crom WR; Abromowitch M; Pui CH; Evans WE
J Pediatr; 1987 Oct; 111(4):606-12. PubMed ID: 2958611
[TBL] [Abstract][Full Text] [Related]
62. Pharmacokinetics of iopamidol 370 in infants and children during ivp.
Beluffi G; Cerutti R; Fiori P; Martini A
Radiol Med; 1989 May; 77(5):493-5. PubMed ID: 2748960
[TBL] [Abstract][Full Text] [Related]
63. Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing.
Strother DR; Glynn-Barnhart A; Kovnar E; Gregory RE; Murphy SB
J Clin Oncol; 1989 Nov; 7(11):1741-7. PubMed ID: 2809687
[TBL] [Abstract][Full Text] [Related]
64. A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma.
Fox E; Busch C; DeBernardo A; Segers B; Gottschalk J; Womer R; Balamuth N; Bagatell R; Balis F
Cancer Chemother Pharmacol; 2021 Jun; 87(6):807-815. PubMed ID: 33677616
[TBL] [Abstract][Full Text] [Related]
65. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients.
Herman RA; Veng-Pedersen P; Hoffman J; Koehnke R; Furst DE
J Pharm Sci; 1989 Feb; 78(2):165-71. PubMed ID: 2715941
[TBL] [Abstract][Full Text] [Related]
66. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate.
Sonneveld P; Schultz FW; Nooter K; Hählen K
Cancer Chemother Pharmacol; 1986; 18(2):111-6. PubMed ID: 3791556
[TBL] [Abstract][Full Text] [Related]
67. Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion.
Wang YM; Kim PY; Lantin E; van Eys DC; Romsdahl MM; Sutow WW
Med Pediatr Oncol; 1978; 4(3):221-9. PubMed ID: 308151
[TBL] [Abstract][Full Text] [Related]
68. Methotrexate Associated Renal Impairment Is Related to Delayed Elimination of High-Dose Methotrexate.
Yang SL; Zhao FY; Song H; Shen DY; Xu XJ
ScientificWorldJournal; 2015; 2015():751703. PubMed ID: 26185782
[TBL] [Abstract][Full Text] [Related]
69. Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats.
Kim MM; Lee SH; Lee MG; Hwang SJ; Kim CK
Biopharm Drug Dispos; 1995 May; 16(4):279-93. PubMed ID: 7548777
[TBL] [Abstract][Full Text] [Related]
70. l-folinic acid versus d,l-folinic acid in rescue of high-dose methotrexate therapy in children.
Etienne MC; Thyss A; Bertrand Y; Touraine R; Rubie H; Robert A; Milano G
J Natl Cancer Inst; 1992 Aug; 84(15):1190-5. PubMed ID: 1635087
[TBL] [Abstract][Full Text] [Related]
71. Plasma 7-Hydroxymethotrexate Levels Versus Methotrexate to Predict Delayed Elimination in Children Receiving High-Dose Methotrexate.
Fabresse N; Devictor B; Pissier C; Chambost H; Lacarelle B; Michel G; Solas C
Ther Drug Monit; 2018 Feb; 40(1):76-83. PubMed ID: 29120974
[TBL] [Abstract][Full Text] [Related]
72. The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats.
Park JM; Ahn BN; Yoon EJ; Lee MG; Shim CK; Kim CK
Biopharm Drug Dispos; 1994 Jul; 15(5):391-407. PubMed ID: 7981428
[TBL] [Abstract][Full Text] [Related]
73. Lack of correlation between methotrexate concentrations in serum, saliva and sweat after 24 h methotrexate infusions.
Schrøder H; Jensen KB; Brandsborg M
Br J Clin Pharmacol; 1987 Oct; 24(4):537-41. PubMed ID: 3689633
[TBL] [Abstract][Full Text] [Related]
74. Methotrexate megadose followed by folate rescue. II. Clearance patterns in patients receiving sequential megadose infusions.
Salasoo S; Irving MG; Freedman A
Med J Aust; 1976 May; 1(22):826-8. PubMed ID: 1085406
[TBL] [Abstract][Full Text] [Related]
75. Pharmacokinetics of leucovorin rescue using a new methotrexate-independent biochemical assay for leucovorin and N5-methyltetrahydrofolate.
Hamel E; Johnson G; Glaubiger D
Cancer Treat Rep; 1981; 65(7-8):545-53. PubMed ID: 7018678
[TBL] [Abstract][Full Text] [Related]
76. Effect of indomethacin on the pharmacokinetics of methotrexate in rabbits.
Najjar TA; Morad AR; Khan RM
Biopharm Drug Dispos; 1992 Jul; 13(5):321-6. PubMed ID: 1498265
[TBL] [Abstract][Full Text] [Related]
77. Serum fluoride in children anaesthetized with enflurane.
Oikkonen M; Meretoja O
Eur J Anaesthesiol; 1989 Nov; 6(6):401-7. PubMed ID: 2583132
[TBL] [Abstract][Full Text] [Related]
78. Evaluation of the Novel Methotrexate Architect Chemiluminescent Immunoassay: Clinical Impact on Pharmacokinetic Monitoring.
Aumente MD; López-Santamaría J; Donoso-Rengifo MC; Reyes-Torres I; Montejano Hervás P
Ther Drug Monit; 2017 Oct; 39(5):492-498. PubMed ID: 28682926
[TBL] [Abstract][Full Text] [Related]
79. Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy.
Christophidis N; Louis WJ; Lucas I; Moon W; Vajda FJ
Cancer Chemother Pharmacol; 1981; 6(1):59-64. PubMed ID: 7273267
[TBL] [Abstract][Full Text] [Related]
80. Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours.
Panetta JC; Roberts JK; Huang J; Lin T; Daryani VM; Harstead KE; Patel YT; Onar-Thomas A; Campagne O; Ward DA; Broniscer A; Robinson G; Gajjar A; Stewart CF
Br J Clin Pharmacol; 2020 Feb; 86(2):362-371. PubMed ID: 31657864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
